Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

CytoSorbents Corp. (CTSO) And Its Breakthrough Medical Technology

|Includes: Cytosorbents Corp (CTSO)

CytoSorbents is a New Jersey based healthcare company that has developed a therapeutic device for blood purification, applicable to kidney disease, sepsis, and other life threatening diseases. CytoSorb™, the company's flagship product, uses what is called hemoperfusion technology, involving the passing of blood over adsorbent substances outside of the body to remove toxins. The specially designed adsorbent material in this case consists of biocompatible, highly porous polymer beads, each containing millions of pores and channels that can be modified to remove substances as small as drugs and as large as antibodies. The system is designed to remove excessive cytokines in critically-ill patients that can lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis.

By addressing one of the most challenging and unmet medical needs, the ability to prevent or mitigate multiple organ failure, which is the leading cause of death in hospital intensive care units, CytoSorb® is a potentially breakthrough therapy. In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts, producing a massive excess of cytokines. Cytokines normally help the body cope with injury, but at these levels they are toxic, creating what is called "cytokine storm," driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure, and often death. Until recently, there were no effective ways to reduce cytokine storm broadly. This is what is addressed by CytoSorb.

In March 2011, CytoSorb™, the company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in clinical situations where cytokines are elevated.

In addition, the company has a development-stage blood purification technology platform called HemoDefend, designed for the blood transfusion industry and intended to reduce transfusion reactions and safeguard the quality and safety of blood products. CytoSorb™ and HemoDefend are just two of a number of different resins that CytoSorbents has designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy drugs during treatment of cancer with high dose regional chemotherapy, drug detoxification, and others.

For additional information, visit the company's websites at CytoSorbents.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net